RxDoctor Payments Data

Rose Hiner, MD

Internal Medicine · Saint Louis, MONPI 1235399817

Payments from drug & device makers

$12,547in general payments, 2019–2025

Across 743 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • AstraZeneca$1K
  • Lilly USA, LLC$970
  • Novo Nordisk$961
  • Pfizer$730
  • Amgen$393
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$12,498100%
  • Entertainment$490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,547 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$100,239
Medicare patients
257
Services billed
1,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide103$186,409
IngrezzaValbenazine Tosylate12$100,879
EliquisApixaban114$82,609
JardianceEmpagliflozin54$68,685
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$35,124
OxycontinOxycodone Hcl12$33,097
FarxigaDapagliflozin Propanediol30$32,531
MounjaroTirzepatide23$31,344
XareltoRivaroxaban34$31,290
TrulicityDulaglutide13$24,538
MyrbetriqMirabegron22$17,528
GemtesaVibegron25$14,794
EntrestoSacubitril/Valsartan15$14,328
Breo ElliptaFluticasone/Vilanterol21$12,472
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$10,679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$961$186,409103 claims
PfizerEliquis, Abrysvo$730$89,744140 claims
Boehringer IngelheimJardiance$74$68,68554 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Arexvy$362$64,671121 claims
Lilly USA, LLCMounjaro, Trulicity$970$55,88236 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,103$53,26271 claims
Johnson & JohnsonXarelto$88$31,29034 claims
Astellas Pharma US IncMyrbetriq$83$17,52822 claims
MerckJanumet, Belsomra$166$16,95230 claims
Sumitomo Pharma America, Inc.Gemtesa$196$14,79425 claims
NovartisEntresto$155$14,32815 claims
AbbVieSynthroid$4,808$5,35060 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →